Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients’ Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine

Table 1

Characteristics of the enrolled patients.

Factor	PPV + JTT; (𝑛=28)	PPV alone; (𝑛=29)	𝑃 value
Age (years)			0.389
Median (range)	66 (50–83)	65 (45–79)
Gender			0.922
Male	18	19
Female	10	10
Performance status			0.706
0	19	22
1	9	7
HLA type			0.753
A24	18	15
A2	12	13
A3 supertype	10	17
A26	5	7
Clinical stage			0.845
IV	19	20
Recurrence	9	9
Location of the main tumor			0.182
Head	6	12
Body-tail	22	17
Number of previous chemotherapy regimens			0.843
0	1	1
1	11	13
2	13	10
>3	3	5
Number of vaccinations			0.443
Median (range)	9 (3–17)	10 (3–18)
Combination chemotherapy			0.640
None	4	0
Gemcitabine	10	13
S-1	5	7
Gemcitabine + S-1	7	8
Others	2	1